UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 3, 2005
                                                 -------------------------------

                              NEOPROBE CORPORATION
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         Delaware                       0-26520                  31-1080091
--------------------------------------------------------------------------------
(State or other jurisdiction          (Commission              (IRS Employer
     of incorporation)                File Number)           Identification No.)

425 Metro Place North, Suite 300, Columbus, Ohio                        43017
--------------------------------------------------------------------------------
    (Address of principal executive offices)                          (Zip Code)

Registrant's telephone number, including area code (614) 793-7500
                                                   -----------------------------


--------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

<PAGE>

Item 2.02. Results of Operations and Financial Condition.

      On November 3, 2005, Neoprobe Corporation (the "Company") issued a press
release regarding its consolidated financial results for the quarter ended
September 30, 2005. A copy of the Company's press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference.

      The information contained in Item 2.02 of this Current Report on Form 8-K,
including exhibit 99.1 hereto, shall not be treated as "filed" for purposes of
the Securities Exchange Act of 1934, as amended.

      Statements contained or incorporated by reference in this Current Report
on Form 8-K which relate to other than strictly historical facts, such as
statements about the Company's plans and strategies, expectations for future
financial performance, new and existing products and technologies, anticipated
regulatory pathways, and markets for the Company's products, are forward-looking
statements. The words "believe," "expect," "anticipate," "estimate," "project,"
and similar expressions identify forward-looking statements that speak only as
of the date hereof. Investors are cautioned that such statements involve risks
and uncertainties that could cause actual results to differ materially from
historical or anticipated results due to many factors including, but not limited
to, the Company's continuing operating losses, uncertainty of market acceptance,
reliance on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited product line and
distribution channels, competition, limited marketing and manufacturing
experience, risks of development of new products, regulatory risks, and other
risks detailed in the Company's most recent Annual Report on Form 10-KSB and
other Securities and Exchange Commission filings. The Company undertakes no
obligation to publicly update or revise any forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Exhibit
Number                              Exhibit Description

99.1              Neoprobe Corporation press release dated November 3, 2005,
                  entitled "Neoprobe Provides Third Quarter Results &
                  Development Update."


                                       2
<PAGE>

                                   SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                       Neoprobe Corporation


Date: November 3, 2005                 By: /s/ Brent L. Larson
                                           -------------------------------------
                                           Brent L. Larson, Vice President
                                             Finance and Chief Financial Officer


                                       3
{"company-data": {"conformed-name": "NEOPROBE CORP", "cik": "0000810509", "assigned-sic": "3841", "irs-number": "311080091", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-26520", "film-number": "051177256"}, "business-address": {"street1": "425 METRO PLACE N", "street2": "STE 400", "city": "DUBLIN", "state": "OH", "zip": "43017", "phone": "6147937500"}, "mail-address": {"street1": "425 METRO PLACE NORTH", "street2": "SUITE 400", "city": "DUBLIN", "state": "OH", "zip": "43017"}}
UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 3, 2005
                                                 -------------------------------

                              NEOPROBE CORPORATION
--------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

         Delaware                       0-26520                  31-1080091
--------------------------------------------------------------------------------
(State or other jurisdiction          (Commission              (IRS Employer
     of incorporation)                File Number)           Identification No.)

425 Metro Place North, Suite 300, Columbus, Ohio                        43017
--------------------------------------------------------------------------------
    (Address of principal executive offices)                          (Zip Code)

Registrant's telephone number, including area code (614) 793-7500
                                                   -----------------------------

--------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.

      On November 3, 2005, Neoprobe Corporation (the "Company") issued a press
release regarding its consolidated financial results for the quarter ended
September 30, 2005. A copy of the Company's press release is furnished as
Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by
reference.

      The information contained in Item 2.02 of this Current Report on Form 8-K,
including exhibit 99.1 hereto, shall not be treated as "filed" for purposes of
the Securities Exchange Act of 1934, as amended.

      Statements contained or incorporated by reference in this Current Report
on Form 8-K which relate to other than strictly historical facts, such as
statements about the Company's plans and strategies, expectations for future
financial performance, new and existing products and technologies, anticipated
regulatory pathways, and markets for the Company's products, are forward-looking
statements. The words "believe," "expect," "anticipate," "estimate," "project,"
and similar expressions identify forward-looking statements that speak only as
of the date hereof. Investors are cautioned that such statements involve risks
and uncertainties that could cause actual results to differ materially from
historical or anticipated results due to many factors including, but not limited
to, the Company's continuing operating losses, uncertainty of market acceptance,
reliance on third party manufacturers, accumulated deficit, future capital
needs, uncertainty of capital funding, dependence on limited product line and
distribution channels, competition, limited marketing and manufacturing
experience, risks of development of new products, regulatory risks, and other
risks detailed in the Company's most recent Annual Report on Form 10-KSB and
other Securities and Exchange Commission filings. The Company undertakes no
obligation to publicly update or revise any forward-looking statements.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

Exhibit
Number                              Exhibit Description

99.1              Neoprobe Corporation press release dated November 3, 2005,
                  entitled "Neoprobe Provides Third Quarter Results &
                  Development Update."

                                       2
SIGNATURES

      Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                       Neoprobe Corporation

Date: November 3, 2005                 By: /s/ Brent L. Larson
                                           -------------------------------------
                                           Brent L. Larson, Vice President
                                             Finance and Chief Financial Officer

                                       3